Abstract
Gliomas are the most common primary brain tumors and account for 40% of all central nervous system neoplasms. Glioblastoma multiforme (GBM) is the most malignant glioma and is characterized by highly infiltrative and neurologically destructive growth patterns. Despite new advances in surgical intervention, radiotherapy, chemotherapy, and a variety of molecular target specific therapies, the median survival of patients with GBM did not change in the last two decades. Today, most GBM patients still die in less than a year [1]. Therefore, it is essential to identify novel molecular targets that may be suitable for treatment and prevention of GBM.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Caveene WK, DePinho RA: Malignant glioma: genetics and biology of grave matter. Gen Develop, 2001; 15:1311–1333.
Ledwozyw A, Lutnicki K: Phospholipids and fatty acids in human brain tumors. Acta Physiol Hungarica 1992; 79:381–387.
Kokoglu E, Tuter Y, Yazici 2, Sandicki KS, Sonmez H, Ulakoglu EZ, Ozyurt E: Profiles of the fatty acids in the plasma membrane of human brain tumors. Cancer Biochem Biophys 1998; 16:301–312.
Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001; 61:4375–4381.
Simmet T, Luck W, Winking M, Delank WK, Peskar BA: Identification and characterization of cysteinyl-leukotriene formation in tissue slices from human intracranial tumors: evidence for their biosynthesis under in vivo conditions. J Neurochem 1990; 54:2091–2099.
Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Geatani P, Paoletti P: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989; 49:1505–1058.
Funk CD: Prostaglandins and Leukotrienes: Advances in eicosanoid biology. Science 2001; 294:1871–1875.
Romano M, Catalano A, Nutini M, D’Urbano E, Crescenzi C, Claria J, Libner R, Davi G Procopio A: 5-Lipoxygenase regulates malignant mesothelioma cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15:2326–2336.
Tong W-g, Ding X-Z, Witt RC, Adrian TE: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Therap 2002; 1:929–935.
Boado RJ, Pardridge WM, Vinters HV, Black KL: Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: Evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 1992; 89:9044–9048.
Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2000; 91:737–743.
Woods JW, Evans JF, Ethier D, Scott S, Vickers PH, Hearn L, Heibein JA, Charleson S, Dinger II: 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178:1935–1946.
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8:467–483.
Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exper Therap 1992;261:1143–1146.
Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL: Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999; 59:2223–2228.
Park YS, Lee JH, Bondar J, Harwalker JA, Safayhi H, and Golubic M: Cytotoxic action of acety1-11-keto-β-boswellic acid (AKBA) on meningioma cells. Planta Medica 2002; 68:397–401.
Glaser T, Winter S, Groscurth P, et al: Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999; 80:756–765.
Park YS, Lee JH, Barnett GH, Bondar J, Harwalkar JA, Safayhi H, Golubic M: Frankincense-derived boswellic acids inhibit growth and motility of brain tumor cells. Complementary Therapies Med 2002; 10:117–118.
Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker DK: Boswellic acids inhibit glioma growth: a new treatment option? J Neurooncol 2000; 46: 97–103.
Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996; 97:806–813.
Hennig R, Ding X-Z, Tong W-G, Schneider MB, Standop J, Friess H, Buchler MW, Pour PM, Adrian TE: 5-Lipoxygenase and Leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161:421–428.
Nielsen CK, Ohd JF, Sjolander A: The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. In Advances in Prostaglandin, Leukotriene and Other Bioactive Lipid Research: Basic Science and Clinical Applicaions, 2003, Kluwer Academic Plenum Publishers, New York (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Golubic, M., Prayson, R.A., Vargo, L., Bondar, J., Barnett, G.H. (2003). Increased Expression of 5-Lipoxygenase In Glioblastoma Multiforme. In: Yazici, Z., Folco, G.C., Drazen, J.M., Nigam, S., Shimizu, T. (eds) Advances in Prostaglandin, Leukotriene, and other Bioactive Lipid Research. Advances in Experimental Medicine and Biology, vol 525. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9194-2_44
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9194-2_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4831-3
Online ISBN: 978-1-4419-9194-2
eBook Packages: Springer Book Archive